去势抵抗性前列腺癌内脏转移患者的发生率与生存:荷兰CAPRI登记研究结果
该真实世界人群研究纳入CAPRI登记库2010至2016年去势抵抗性前列腺癌患者,随访至2017年,分析内脏转移的发生率、治疗及生存。3602例患者中457例(12.7%)诊断内脏转移,肝转移中位总生存8.6个月,肺转移18.3个月,肝肺均转移10.9个月(p<0.001)。尽管随访中影像筛查率增加,但CRPC诊断时至第6线治疗时仍有80%至40%的患者未筛查内脏转移。
要点
- CAPRI登记库3602例CRPC患者中457例(12.7%)诊断内脏转移,肝转移230例、肺转移161例、肝肺均转移66例。
- 自首次内脏转移诊断起中位总生存:肝转移8.6个月、肺转移18.3个月、肝肺均转移10.9个月(p<0.001)。
- 校正预后因素后肺转移患者总生存显著优于肝转移(HR 0.650,p=0.001)。
核心结论
- 真实世界分析显示尽管随访中影像分期率增加,但CRPC诊断时至第6线治疗时仍有80%至40%的患者在开始全身治疗时未筛查内脏转移。
- 内脏转移及其位置是关键预后特征,影响生存和治疗决策,因此作者认为有必要对CRPC患者进行常规分期。
研究设计与样本
- 真实世界人群研究,纳入CAPRI登记库2010至2016年去势抵抗性前列腺癌患者,随访至2017年。
- 结局包括接受影像学内脏转移筛查的患者比例、CRPC诊断时及每线治疗开始时内脏转移患者比例。
- 根据首次内脏转移诊断时转移位置(肺、肝或两者)分组,结局为总生存。
- 统计方法包括描述性分析、Kaplan-Meier法和Cox比例风险回归分析。
主要发现
- 3602例CAPRI登记库患者中457例(12.7%)随访期间诊断内脏转移:肝转移230例、肺转移161例、肝肺均转移66例。
- 每线治疗中接受内脏转移影像筛查的患者比例增加,内脏转移发生率亦增加。
- CRPC诊断时至第6线治疗时,仍有80%至40%的患者在开始全身治疗时未筛查内脏转移。
- 自首次内脏转移诊断起中位总生存:肝转移8.6个月、肺转移18.3个月、肝肺均转移10.9个月(p<0.001)。
- 校正预后因素后,肺转移患者总生存显著优于肝转移患者(HR 0.650,p=0.001)。
临床怎么用
- 作者认为内脏转移及其位置是关键预后特征,影响生存和治疗决策,因此有必要对CRPC患者进行常规分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this real-world population study is to investigate incidence and treatment of visceral metastases (VMs) in castration resistant prostate cancer (CRPC) patients and their survival. METHODS: CRPC-patients in the CAPRI-registry between 2010 and 2016 were included in the analyses and followed till 2017. Outcomes were proportion of patients radiologically screened for VMs and proportion of patients with VMs at CRPC-diagnosis and at the start of every treatment line. Groups have been created based on location of VMs (lung, liver, or both) at date of first VM diagnosis. The outcome for these groups was overall survival (OS). Statistics included descriptive analyses, Kaplan-Meier method, and Cox proportional hazard regression analysis for survival analyses. RESULTS: Of 3602 patients from the CAPRI registry, 457 patients (12.7%) were diagnosed with VMs during follow-up: 230 patients with liver, 161 with lung, and 66 with both liver and lung metastases. The proportion of patients radiologically screened for VMs increased per treatment line as did the occurrence rate of VMs. However, 80% of patients at CRPC diagnosis to 40% in the 6th line were not screened for VMs at the start of a systemic treatment. Median OS was 8.6 months for patients with liver, 18.3 with lung and 10.9 with both liver and lung metastases (p < 0.001) from date of first VM diagnosis. After correction for prognostic factors patients with lung metastases had significantly better OS than patients with liver metastases (HR 0.650, p = 0.001). CONCLUSION: This real-world analysis showed that despite the increased rate of radiological staging during follow-up, still 80% to 40% of the patients (CRPC diagnosis to 6th treatment line respectively) were not screened for VMs at the start of a systemic treatment. VMs and location of VMs are key prognostic patient characteristics, impacts survival and have implications for treatment decisions, so routine staging of CRPC-patients is warranted. CLINICAL TRIAL IDENTIFICATION: The CAPRI study is registered in the Dutch Trial Registry as NL3440 (NTR3591).
引用
- van den Bergh GPA, Kuppen MCP, Westgeest HM, et al. Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry. Prostate Cancer Prostatic Dis. 2022. PMID: 36224377. doi:10.1038/s41391-022-00605-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。